News & Events
Hatchtech appoints Stewart Washer chairman
18 / 12 / 2007
Strengthens commercial expertise for expansion of world class insect control technologies Anti-egg hatching technology company Hatchtech Pty Ltd has appointed Dr Stewart Washer as chairman of its board of directors. Dr Washer is best known for his past 15 years…
Continued Advancement in Heart Failure Therapies
17 / 12 / 2007
Sunshine Heart, Inc. (ASX: SHC) welcomed Thoratec Corporation's (NASDAQ: THOR) achievement of another milestone in the market growth of heart failure therapies. A U.S. Food & Drug Administration (FDA) advisory panel recommended unanimously that the agency approve, with conditions, the U.S.…
ChemGenex Announces Poster Presentations at the 49th Annual Meeting of the American Society of Hematology
17 / 12 / 2007
ChemGenex Investigators Report Omacetaxine Effective in Killing CML Stem Cells in Animal Model Studies
11 / 12 / 2007
Key Leukemia Protein Mcl-1 Preferentially Down-Regulated by Omacetaxine ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today that pre-clinical data characterizing the mechanism of action of omacetaxine mepesuccinate (formerly known as Ceflatoninr)…
Granting of Important US Patent
11 / 12 / 2007
Sunshine Heart is pleased to report that the US Patent Office has granted its patent application entitled "A Fluid Pressure Generating Means" as US Patent 7,306,558. This patent provides the Company with broad patent coverage for a fully implanted heart assist driver of novel design that is…
ChemGenex Investigators Report Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients with the T315I Mutation
10 / 12 / 2007
Complete Hematological and/or Complete Cytogenetic Responses in 64% of Chronic Phase Patients Conference call to be held on Thursday, December 13 Australian Eastern Daylight Time (Wednesday, December 12 in the USA and Europe) ChemGenex Pharmaceuticals (ASX: CXS,…
Portland Orthopaedics AGM: US business strategy is working, margins improving
05 / 12 / 2007
Presentations to the Portland Orthopaedics Limited (ASX:PLD) annual general meeting and answers to questions arising at that AGM contained key performance information including: US sales have grown 345% overall in the 12 months to Sep 07 US surgeon users…
ChemGenex Announces Shareholder Approval to Demerge Verva Pharmaceuticals
29 / 11 / 2007
- ChemGenex to Focus on Late-stage Cancer Portfolio - Verva Pharmaceuticals merger with Adipogen Pharmaceuticals on track ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) today announced that at the company's Annual General Meeting yesterday it…
New Data Presented on the Renessar Treatment for Female Stress Urinary Incontinence
09 / 11 / 2007
6 month results from long term durability study presented at Western Section meeting of the American Urological Association Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that six month data from its post-market,…
Cryptopharma raises $0.8m to progress cystic fibrosis drug Cryptopharma appoints David Crump as new CEO
17 / 10 / 2007
Melbourne-based pulmonary inflammation biotechnology company Cryptopharma Pty Ltd has appointed Dr David Crump as chief executive officer and completed an $800,000 capital raising. David Crump is a qualified medical practitioner with comprehensive experience in drug…
ChemGenex Announces Positive Preliminary Data from Phase 2/3 Clinical Trial of Ceflatoninr at International Conference
10 / 10 / 2007
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today the first presentation of early clinical data from its registration-directed phase 2/3 clinical study of Ceflatoninr (omacetaxine mepesuccinate) at the Fourth ESH International Conference on Chronic Myeloid Leukaemia in…
Sunshine Heart Profiled at Washington DC AdvaMed 2007 MedTech Conference
08 / 10 / 2007
Don Rohrbaugh, Chief Executive Officer of Sunshine Heart, Inc. (ASX: SHC) was among a select number of medical technology industry leaders invited to present at the prestigious AdvaMed 2007 MedTech Conference held in Washington DC, USA. The AdvaMed 2007 MedTech…
ChemGenex Appoints Experienced Biotechnology Executive as Chief Medical Officer Chief Medical Officer
08 / 10 / 2007
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) today announced the appointment of Adam R. Craig MD, PhD, MBA as Senior Vice President and Chief Medical Officer. In this position, Dr. Craig will leverage more than 15 years of clinical, oncology and drug development experience to…
ChemGenex Announces Second Publication Demonstrating Activity of Ceflatoninr in T315I-Positive Chronic Myeloid Leukemia (CML)
24 / 09 / 2007
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today the publication of a clinical communication in Blood (the journal of the American Society of Hematology) demonstrating clinical activity of the companys lead compound, Ceflatoninr (Homoharringtonine, HHT1)…
Retirement of Dr Richard Lin as Director
20 / 09 / 2007
Sunshine Heart, Inc (ASX: SHC) has today announced that Dr Richard Lin, a partner of Three Arch Partners, will be retiring as a director of the Company at its annual general meeting to be held on 15 November 2007. Sunshine Heart Chairman, Malcolm McComas, said "Rich Lin…
Major Shareholders Commit Early to Second Tranche Funding
19 / 09 / 2007
Sunshine Heart, Inc. (ASX: SHC) has previously announced (6 September 2006) that following FDA approval of its IDE application to commence a clinical trial in the USA, major shareholders CM Capital Investments (CM Capital) and GBS Venture Partners (GBS) will subscribe for a total of $6…
Phase III Trial Finds Pharmaxis' Bronchitol Effective
29 / 08 / 2007
Pharmaxis (ASX: PXS, NASDAQ: PXSL) today announced that its Phase III B301 study of Bronchitol for the treatment of people with bronchiectasis has met its two primary efficacy endpoints: quality of life and mucus clearance. Data from the 362 subject study demonstrated a…
CogState Signs Agreement for Phase IV Trial with Pfizer
21 / 08 / 2007
Key points: Phase IV trial conducted by Pfizer throughout Europe will use CogState technology and services Cognition, as measured by change in CogState score, is the primary endpoint for the trial CogState Ltd (ASX:CGS) announced today that it has signed an…
C-PulseTM Pilot Clinical Trial Results Presented FDA Meeting Scheduled for US Clinical Trial
14 / 08 / 2007
Sunshine Heart, Inc (ASX: SHC) announced today that the results of the C-PulseTM Pilot Clinical Trial were presented by Mr Paget Milsom FRACS at the Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand (CSANZ) on Saturday 11 August, 2007 in Christchurch, New…
ChemGenex to Present at Canaccord Adams' 27th Global Growth Conference
07 / 08 / 2007
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today that it will deliver a presentation at the 27th Annual Canaccord Adams Global Growth Conference in Boston, Massachusetts. Greg Collier, Ph.D., Chief Executive Officer and Managing Director of ChemGenex, is scheduled…
CogState Signs Second Agreement with GlaxoSmithKline
13 / 07 / 2007
CogState Ltd (ASX:CGS) announced today that it is has signed a second contract with global research-driven pharmaceutical company, GlaxoSmithKline, for the use of CogState's cognitive testing technology and associated services in a clinical trial due to start this year. Mr…
CogState Signs Second Agreement with Merck & Co., Inc.
09 / 07 / 2007
CogState Ltd (ASX:CGS) announced today that it is has signed a second contract with global research-driven pharmaceutical company, Merck & Co., Inc. for the use of CogState's cognitive testing technology and associated services in a clinical trial due to start this year.